-
Access to HealthcareGlobal Health PartnershipsMedical InnovationsOncologySocial Commitment
-
Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.
Access to HealthcareCancerOncologySocial CommitmentTargeted Therapy -
Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.
Access to HealthcareCancerNovartis AccessSocial Commitment -
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.CancerLiving With DiseaseOncologyPatient VoicesSocial Commitment
-
Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the…Social CommitmentGlobal Health PartnershipsFuture of HealthcareEthical Business
-
Basel, September 30, 2021 — At its eighth annual ESG investor event hosted today, Novartis shared progress against its Environmental, Social and Governance (ESG) targets and updated on its most material ESG topics, including access to medicines, patient health and safety, innovation and ethical standards.Sustainable DevelopmentSocial CommitmentNovartis AccessAccess to Healthcare
-
Basel, September 16, 2020 — Novartis today announced the pricing of a EUR 1.85 billion sustainability-linked bond (SLB), reinforcing its commitment to ESG principles and the 2025 Patient Access Targets announced earlier this month.Social CommitmentReimagine MedicineNovartis AccessFuture of HealthcareAccess to Healthcare
-
Basel, November 19, 2020 — Novartis today announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve 100% renewable electricity in its European operations…Sustainable DevelopmentSocial CommitmentReimagine MedicineFuture of Healthcare
-
Basel, January 29, 2021 — A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to…Social CommitmentReimagine Medicine
-
Basel, January 29, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site…Social CommitmentReimagine Medicine
-
Basel, March 17, 2020 - Vas Narasimhan, CEO of Novartis, said: “We are dealing with an extraordinary and unprecedented public health crisis that requires an incredible level of involvement and collaboration across government, society and business. As a medicines company present in over 140 countries, we are stepping in to provide additional…Social CommitmentReimagine MedicineAccess to Healthcare
-
Basel, March 20, 2020 - Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing…Social CommitmentReimagine MedicineAccess to Healthcare
-
Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.
-
Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.